Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Asterias Biotherapeutics, Inc. (AST)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-17Dec-31-16Dec-31-15Dec-31-14Dec-31-13Dec-31-12
   10-K10-K10-K10-K10-K10-K
Revenues:  
    Royalties from product sales  0.30.30.50.2  
    Licenses revenue   0.1    
    Other  3.76.63.01.0  
Total revenues   [+]4.07.03.61.20.00.0
            Revenue growth   [+]-41.9%94.1%192.6%   
Cost of goods sold  0.20.10.30.10.01.5
Gross profit  3.96.83.31.10.0-1.5
            Gross margin  95.9%98.2%92.5%92.2%  
Selling, general and administrative   [+]10.515.57.95.33.80.8
Research and development  26.625.517.313.34.3 
Other operating expenses      35.0-1.5
EBITDA   [+]-29.5-30.3-18.7-12.1-42.2 
            EBITDA margin  -728.7%-435.2%-520.9%-992.0%  
Depreciation  1.11.20.60.50.2 
EBITA  -30.6-31.4-19.2-12.7-42.4-0.8
            EBITA margin  -756.2%-452.1%-536.6%-1035.3%  
Amortization of intangibles  2.72.72.74.80.7 
EBIT   [+]-33.3-34.1-21.9-17.5-43.1-0.8
            EBIT margin  -822.6%-490.7%-611.6%-1426.6%  
Non-recurring items   [+]    -17.5 
Interest expense  0.50.50.30.00.0 
Other income (expense), net   [+]5.3-3.10.00.00.00.0
Pre-tax income  -28.4-37.8-22.3-17.5-25.7-0.8
Income taxes  0.0-2.3-7.3-7.4-3.30.0
            Tax rate  0.0%6.1%32.6%42.2%12.8%0.0%
Net income  -28.4-35.5-15.0-10.1-22.4-0.8
            Net margin  -701.9%-510.3%-418.8%-824.9%  
   
Basic EPS   [+]($0.56)($0.83)($0.42)($0.33)($2.90)($14.69)
Diluted EPS   [+]($0.56)($0.83)($0.42)($0.33)($2.90)($14.69)
   
Shares outstanding (basic)   [+]50.342.935.430.77.70.1
Shares outstanding (diluted)   [+]50.342.935.430.77.70.1
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy